| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/MDS.870110117 |
| P698 | PubMed publication ID | 8771074 |
| P2093 | author name string | Bédard PJ | |
| Blanchet PJ | |||
| Grondin R | |||
| P433 | issue | 1 | |
| P304 | page(s) | 91-94 | |
| P577 | publication date | 1996-01-01 | |
| P1433 | published in | Movement Disorders | Q1486418 |
| P1476 | title | Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates | |
| P478 | volume | 11 |
| Q45711950 | Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment |
| Q44237901 | Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa |
| Q48165059 | Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content |
| Q34070917 | Continuous dopamine-receptor stimulation in early Parkinson's disease |
| Q64952195 | Dopamine receptor subtypes as targets for the pharmacotherapy of Parkinson's disease |
| Q73125101 | Dopamine-receptor stimulation: biobehavioral and biochemical consequences |
| Q36577320 | Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease |
| Q37685666 | From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease |
| Q34413699 | Functional and pathophysiological models of the basal ganglia |
| Q49234399 | Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor |
| Q73986070 | Increased behavioral response to dopaminergic stimulation of the subthalamic nucleus after nigrostriatal lesions |
| Q33770264 | Levodopa in Parkinson's disease: neurotoxicity issue laid to rest? |
| Q48165678 | Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease |
| Q48279502 | Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging |
| Q41718467 | Models of basal ganglia function and pathophysiology of movement disorders. |
| Q41509268 | Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease |
| Q39229450 | Non-human primate models of PD to test novel therapies |
| Q33714121 | Rationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives |
| Q33545304 | Surgical options in Parkinson's disease |
| Q35105740 | The Fluctuating Parkinsonian Patient - Clinical and Pathophysiological Aspects |
| Q35062598 | The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease |
| Q43629628 | Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study |
Search more.